Open-label randomized trial of titrated disease management for patients with hypertension: Study design and baseline sample characteristics.

Published

Journal Article

Despite the availability of efficacious treatments, only half of patients with hypertension achieve adequate blood pressure (BP) control. This paper describes the protocol and baseline subject characteristics of a 2-arm, 18-month randomized clinical trial of titrated disease management (TDM) for patients with pharmaceutically-treated hypertension for whom systolic blood pressure (SBP) is not controlled (≥140mmHg for non-diabetic or ≥130mmHg for diabetic patients). The trial is being conducted among patients of four clinic locations associated with a Veterans Affairs Medical Center. An intervention arm has a TDM strategy in which patients' hypertension control at baseline, 6, and 12months determines the resource intensity of disease management. Intensity levels include: a low-intensity strategy utilizing a licensed practical nurse to provide bi-monthly, non-tailored behavioral support calls to patients whose SBP comes under control; medium-intensity strategy utilizing a registered nurse to provide monthly tailored behavioral support telephone calls plus home BP monitoring; and high-intensity strategy utilizing a pharmacist to provide monthly tailored behavioral support telephone calls, home BP monitoring, and pharmacist-directed medication management. Control arm patients receive the low-intensity strategy regardless of BP control. The primary outcome is SBP. There are 385 randomized (192 intervention; 193 control) veterans that are predominately older (mean age 63.5years) men (92.5%). 61.8% are African American, and the mean baseline SBP for all subjects is 143.6mmHg. This trial will determine if a disease management program that is titrated by matching the intensity of resources to patients' BP control leads to superior outcomes compared to a low-intensity management strategy.

Full Text

Duke Authors

Cited Authors

  • Jackson, GL; Weinberger, M; Kirshner, MA; Stechuchak, KM; Melnyk, SD; Bosworth, HB; Coffman, CJ; Neelon, B; Van Houtven, C; Gentry, PW; Morris, IJ; Rose, CM; Taylor, JP; May, CL; Han, B; Wainwright, C; Alkon, A; Powell, L; Edelman, D

Published Date

  • September 2016

Published In

Volume / Issue

  • 50 /

Start / End Page

  • 5 - 15

PubMed ID

  • 27417982

Pubmed Central ID

  • 27417982

Electronic International Standard Serial Number (EISSN)

  • 1559-2030

Digital Object Identifier (DOI)

  • 10.1016/j.cct.2016.07.009

Language

  • eng

Conference Location

  • United States